Synthesis, performance, and application of molecularly imprinted membranes: A review

Biosorption of nickel(II) ions from aqueous solution onto Sargassum wightii has been studied and the equilibrium isotherms were determined. The experimental data obtained at different pH conditions (pH 3.0-4.5) have been analyzed using five two-parameter models (Langmuir, Freundlich, Temkin, Dubinin-Radushkevich and Flory-Huggins) and five three-parameter models (Redlich-Peterson, Sips, Khan, Radke-Prausnitz and Toth). In order to determine the best fit isotherm, three error analysis methods were used to evaluate the data: correlation coefficient, residual root mean square error and chi-square test. The error analysis demonstrated that the three-parameter models better described the nickel biosorption data compared to two-parameter models. In particular, Toth equation provided the best model for nickel biosorption data at all pH conditions examined.

Drug delivery systems are widely researched and developed to improve the delivery of pharmaceutical compounds and molecules. The last few decades have seen a marked growth of the field fueled by increased number of researchers, research funding, venture capital and the number of start-ups. Collectively, the growth has led to novel systems that make use of micro/nano-particles, transdermal patches, inhalers, drug reservoir implants and antibody-drug conjugates. While the increased research activity is clearly an indication of proliferation of the field, clinical and commercial translation of early-stage research ideas is critically important for future growth and interest in the field. Here, we will highlight some of the examples of novel drug delivery systems that have undergone such translation. Specifically, we will discuss the developments, advantages, limitations and lessons learned from: (i) microparticle-based depot formulations, (ii) nanoparticle-based cancer drugs, (iii) transdermal systems, (iv) oral drug delivery systems, (v) pulmonary drug delivery, (vi) implants and (vii) antibody-drug conjugates. These systems have impacted treatment of many prevalent diseases including diabetes, cancer and cardiovascular diseases, among others. At the same time, these systems are integral and enabling components of products that collectively generate annual revenues exceeding US $100 billion. These examples provide strong evidence of the clinical and commercial impact of drug delivery systems.